References
- Hall DB, Montaner JSG, Reiss P, et al. Induction-main-tenance antiretroviral therapy: proof of concept. AIDS 1998; 12: F41–F44.
- Montaner JS. Induction/maintenance treatment regi-mens for HIV. JAMA 1999; 281: 1680–1682.
- Oh MD, Merrill DP, Hirsch MS. Induction and mainte-nance treatment regimens for HIV-1 infection in vitro. Antiviral Ther 1999; 4: 29–34.
- Gallant JE. Strategies for long-term success in the treat-ment of HIV infection. JAMA 2000; 283: 1329–1334.
- Reijers MHE, Weyerling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185–190.
- Havlir DV, Marschner IC, Hirsch MS, et al, for the ACTG Study 343 Team. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV-RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261–1268.
- Pialoux G, Raffi F, Brun-Vezinet F, et al for the Trilêge Study Team. A randomized trial of three maintenance regi-mens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998; 339: 1269–1276.
- Dieleman JP, Gyssens IC, Sturkenboom MJ, Niesters HG, Van der Ende ME. Substituting nevirapine for protease inhibitors because of intolerance. AIDS 1999; 13: 1423–1424.
- Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege Study Team. JAMA 2000; 283: 205–211.
- Nieuwkerk PT, Reijers MHE, Weigel HM, Lange JMA, Sprangers MAC. Quality of life in maintenance vs prolonged induction therapy for HIV. JAMA 2000; 284: 178–179.
- Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805–810.
- Barreiro P, Soriano V, Blanco F, Casimiro C, Jose de La Cruz J, González-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 807–812.
- De Luca A, Baldini F, Cingolani A, et al. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. AIDS 2000; 14: 1655–1656.
- Barreiro P, De Mendoza C, Soriano V, González-Lahoz J. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. AIDS 2000; 14: 207–208.
- Jensen-Fangel S, Kirk O, Larsen L, et al. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study. Scand J Infect Dis 1999; 31: 489–493.